Old and New Biomarkers for Infection, Inflammation, and Autoimmunity in Treatment-Resistant Affective and Schizophrenic Spectrum Disorders

被引:7
|
作者
Scheiber, Christian [1 ]
Schulz, Tanja [1 ]
Schneider, Julian M. [1 ]
Bechter, Karl [2 ]
Schneider, E. Marion [1 ]
机构
[1] Ulm Univ Hosp, Div Expt Anaesthesiol, D-89081 Ulm, Germany
[2] Ulm Univ, Clin Psychiat & Psychotherapy 2, D-89312 Gunzburg, Germany
基金
欧盟地平线“2020”;
关键词
affective disorders; schizophrenia; cerebrospinal fluid; biomarkers; immune phenotypes; monocytes; CEREBROSPINAL-FLUID S100B; DEPRESSION; ACTIVATION; MECHANISM; MONOCYTES; DISEASES; SIGLECS; BINDING; PROTEIN; CELLS;
D O I
10.3390/ph15030299
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Affective (AF) and Schizophrenic (SZ) Spectrum disorders manifest with risk factors, involving inflammatory processes linked to infections and autoimmunity. This study searched for novel biomarkers in cerebrospinal fluid (CSF) and peripheral blood. A total of 29 AF and 39 SZ patients with treatment-resistant disease were included. In CSF, the chemokine IL-8 was significantly elevated in AF and SZ patients. IL-8 promotes chemotaxis by neutrophils and may originate from different tissues. S100B, a glia-derived brain damage marker, was higher in CSF from AF than SZ patients. Among the plasma-derived biomarkers, ferritin was elevated in AF and SZ. Soluble CD25, indicating T-reg dysfunction, was higher in SZ than in AF patients. Interferon-gamma, implying virus-specific immune activation, was positive in selective AF patients, only. Both groups showed elevated expression of immunosuppressive CD33 on monocytes, but higher amounts of CD123(+) plasmacytoid dendritic cells were restricted to SZ. In conclusion, chemotactic IL-8 indicates neuronal stress and inflammation in the CSF of both groups. Novel plasma-derived biomarkers such as sCD25 and monocytic CD33 distinguish SZ from AF with an autoimmune phenotype.
引用
收藏
页数:15
相关论文
共 5 条
  • [1] Pharmacokinetic and pharmacodynamic drug interactions with polypharmacotherapy of treatment-resistant affective and obsessive-compulsive disorders
    Carson, SW
    PSYCHOPHARMACOLOGY BULLETIN, 1996, 32 (04) : 555 - 568
  • [2] Long-term symptomatic and functional outcome following an intensive inpatient multidisciplinary intervention for treatment-resistant affective disorders
    Wooderson, Sarah C.
    Fekadu, Abebaw
    Markopoulou, Kalypso
    Rane, Lena J.
    Poon, Lucia
    Juruena, Mario F.
    Strawbridge, Rebecca
    Cleare, Anthony J.
    JOURNAL OF AFFECTIVE DISORDERS, 2014, 166 : 334 - 342
  • [3] USE OF INTRANASAL ESKETAMINE IN A GIRL WITH TREATMENT-RESISTANT DEPRESSION AND AUTISM SPECTRUM DISORDERS: A CASE REPORT
    Olivola, Miriam
    Arienti, Vincenzo
    Bassetti, Nicola
    Civardi, Serena
    Brondino, Natascia
    EXCLI JOURNAL, 2022, 21 : 540 - 543
  • [4] Antipsychotic polypharmacy and augmentation strategies prior to clozapine initiation: a historical cohort study of 310 adults with treatment-resistant schizophrenic disorders
    Thompson, Joseph V.
    Clark, Joanne M.
    Legge, Sophie E.
    Kadra, Giouliana
    Downs, Johnny
    Walters, James T. R.
    Hamshere, Marian L.
    Hayes, Richard D.
    Taylor, David
    MacCabe, James H.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2016, 30 (05) : 436 - 443
  • [5] Utilizing the Systemic Immune-Inflammation Index and Blood-Based Biomarkers in Association with Treatment Responsiveness amongst Patients with Treatment-Resistant Bipolar Depression
    Decker, Kyle
    Murata, Stephen
    Baig, Nausheen
    Hasan, Sakibur
    Halaris, Angelos
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (08):